Please Wait.....
Report
Acute Kidney Injury (AKI) - Epidemiology Forecast - 2032
Market Report I 2022-09-01 I 77 Pages I DelveInsight
DelveInsight's " Acute Kidney Injury - Epidemiology Forecast- 2032" report delivers an in-depth understanding of the AKI, historical and forecasted epidemiology trends in the United States, the EU-5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Geography Covered
- The United States
- The EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
Acute Kidney Injury Disease Understanding and Treatment Algorithm
Acute Kidney Injury Overview
AKI is commonly defined as an abrupt decline in renal function, clinically manifesting as a reversible acute increase in nitrogen waste products measured by blood urea nitrogen (BUN) and serum creatinine levels over the course of hours to weeks. Signs and symptoms of AKI includes, nausea, vomiting, weakness, dizziness and, pain in lower back. Some patients are asymptomatic (no noticeable symptoms) and others may have generalized non-specific (not specific to kidneys) symptoms.
Acute Kidney Injury Diagnosis
The diagnosis of AKI is traditionally based on a rise in serum creatinine and/or fall in urine output. The laboratory assessment includes the measurement of Serum Creatinine Level, Urinalysis, renal biopsy and others.
Acute Kidney Injury Treatment
The treatment for AKI depends on the cause of the condition. Most people need to stay in the hospital during treatment and until the recovery of the kidneys. Some possible treatments include temporary hemodialysis, medicines to control the amounts of vitamins and minerals in blood, treatments to keep the right amount of fluid in the blood. There is no approved treatment for AKI, the current treatment practices use conventional therapies (vasopressor, diuretics, statins and others) and renal replacement therapies.
Acute Kidney Injury Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Population of AKI in Hospitalized Patients, Mortality Adjusted Incident Population of AKI in Hospitalized Patients, Stage-specific Incident Population of AKI and, Age-specific Incident Population of AKI in the 7MM market covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Key Findings
This section provides glimpse of the AKI epidemiology in the 7MM
Country Wise- Acute Kidney Injury Epidemiology
- The epidemiology segment also provides the AKI epidemiology data and findings across the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- The total Mortality-adjusted Incident Cases of AKI in the 7MM comprised of 6,470,038 cases in 2021 and are projected to increase during the forecast period.
- The total Mortality-adjusted Incident Cases of AKI in the United States is 2,210,647 in 2021.
- The US contributed to the largest incident population of AKI, accounting for ~ 34% of the 7MM in 2021.
- Among the EU-5 countries, Germany accounted for the highest number of AKI cases, followed by France, whereas Spain accounted for the lowest cases in 2021.
- In Japan, the total mortality-adjusted Incident Cases of AKI was 1,272,824 in 2021 and is anticipated to rise during the forecast period.
- The stage-specific cases of AKI includes stage I, Stage II and, stage III. Out of which maximum cases were reported in stage I AKI followed by stage II and Stage III.
Scope of the Report
- The report covers the descriptive overview of AKI, explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
- Comprehensive insight has been provided into the AKI epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for AKI are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of AKI market; historical and forecasted is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM AKI market.
Report Highlights
- In the coming years, AKI market is set to change due emerging therapies in the pipeline, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics are working to assess challenges and seek opportunities that could influence AKI R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- As per DelveInsight's analysis the subtypes- specific of AKI include Stage I, Stage II and Stage III.
?
AKI Report Insights
AKI Report Insights
- Patient Population
- Therapeutic Approaches
- 7MM Coverage
- AKI Epidemiology Segmentation
Key Questions
Epidemiology Insights:
- What is the disease risk, burden and unmet needs of AKI?
- What is the historical AKI patient pool in the United States, the EU-5 (Germany, France, Italy, Spain, and the UK) and Japan?
- What would be the forecasted patient pool of AKI at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to AKI?
- Out of the above-mentioned countries, which country would have the highest incident population of AKI during the study period (2019-2032)?
- At what CAGR the population is expected to grow across the 7MM during the study period (2019-2032)?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the AKI.
- To understand the future market competition in the AKI market and Insightful review of the SWOT analysis of AKI.
- Organize sales and marketing efforts by identifying the best opportunities for AKI in the US, EU-5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
- The AKI Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources.
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Epidemiology And Methodology
5. Disease Background And Overview
5.1. Introduction
5.2. Symptoms
5.3. Types Of Acute Kidney Injury
5.4. Stages Classification
5.5. Risk Factors
5.6. Etiology
6. Epidemiology And Patient Population
6.1. Key Findings
6.2. Assumptions And Rationale
6.2.1. United States
6.2.2. Eu-5
6.2.3. Japan
6.3. Total Incidence Of Acute Kidney Injury (AKI) In Hospitalized Patients In The 7mm
6.4. Total Mortality Adjusted Incident Population Of AKI In Hospitalized Patients In The 7mm
6.5. The United States
6.5.1. Total Incident Population Of AKI In Hospitalized Patients In The Us
6.5.2. Mortality Adjusted Incident Population Of AKI In Hospitalized Patients In The Us
6.5.3. Stage-Specific Incident Population Of AKI In The Us
6.5.4. Age-Specific Incident Population Of AKI In The Us
6.6. Eu-5
6.6.1. Total Incident Population Of AKI In Hospitalized Patients In Eu-5
6.6.2. Mortality Adjusted Incident Population Of AKI In Hospitalized Patients In Eu-5
6.6.3. Stage-Specific Incident Population Of AKI In The Eu-5
6.6.4. Age-Specific Incident Population Of AKI In The Eu-5
6.7. Japan
6.7.1. Total Incident Population Of AKI In Hospitalized Patients In Japan
6.7.2. Mortality Adjusted Incidence Of AKI In Hospitalized Patients In Japan
6.7.3. Stage-Specific Incident Population Of AKI In Japan
6.7.4. Age-Specific Incidence Of AKI In Japan
7. Appendix
7.1. Bibliography
7.2. Report Methodology
8. Delveinsight Capabilities
9. Disclaimer
10. About Delveinsight
Table 1: Summary of Acute Kidney Injury Market, and Epidemiology (2019-2032)
Table 2: Total Incident Population of AKI in Hospitalized Patients in the 7MM, in Thousands (2019-2032)
Table 3:Mortality Adjusted Incident Population of AKI in Hospitalized Patients in the 7MM, in Thousands (2019-2032)
Table 4: Total Incident Population of AKI in Hospitalized Patients in the US, in Thousands (2019-2032)
Table 5: Mortality Adjusted Incident Population of AKI in Hospitalized Patients in the US, in Thousands (2019-2032)
Table 6: Stage-specific Incident Population of AKI in the US, in Thousand (2019-2032)
Table 7: Age-specific Incident Population of AKI in the US, in Thousands (2019-2032)
Table 8: Total Incidence of AKI in Hospitalized Patients in the EU-5 in Thousands (2019-2032)
Table 9: Mortality Adjusted Incident Population of AKI in Hospitalized Patients in the EU-5, in Thousands (2019-2032)
Table 10: Stage-specific Incident Population of AKI in the EU-5, in Thousands (2019-2032)
Table 11: Age-specific Incident Population of AKI in the EU-5, in Thousands (2019-2032)
Table 12: Total Incident Population of AKI in Hospitalized Patients in Japan, in Thousand (2019-2032)
Table 13: Mortality Adjusted Incident Population of AKI in Hospitalized Patients in Japan, in Thousands (2019-2032)
Table 14: Stage-specific Incident Population of AKI in Hospitalized Patients in Japan, in Thousands (2019-2032)
Table 15: Age-specific Incident Population of AKI in Japan, in Thousands (2019-2032)
Figure1: Summary of Acute Kidney Injury Market, and Epidemiology (2019-2032)
Figure2: Total Incident Population of AKI in Hospitalized Patients in the 7MM, in Thousands (2019-2032)
Figure 3:Mortality Adjusted Incident Population of AKI in Hospitalized Patients in the 7MM, in Thousands (2019-2032)
Figure 4: Total Incident Population of AKI in Hospitalized Patients in the US, in Thousands (2019-2032)
Figure 5: Mortality Adjusted Incident Population of AKI in Hospitalized Patients in the US, in Thousands (2019-2032)
Figure 6: Stage-specific Incident Population of AKI in the US, in Thousand (2019-2032)
Figure 7: Age-specific Incident Population of AKI in the US, in Thousands (2019-2032)
Figure 8: Total Incidence of AKI in Hospitalized Patients in the EU-5 in Thousands (2019-2032)
Figure 9: Mortality Adjusted Incident Population of AKI in Hospitalized Patients in the EU-5, in Thousands (2019-2032)
Figure 10: Stage-specific Incident Population of AKI in the EU-5, in Thousands (2019-2032)
Figure 11: Age-specific Incident Population of AKI in the EU-5, in Thousands (2019-2032)
Figure 12: Total Incident Population of AKI in Hospitalized Patients in Japan, in Thousand (2019-2032)
Figure 13: Mortality Adjusted Incident Population of AKI in Hospitalized Patients in Japan, in Thousands (2019-2032)
Figure 14: Stage-specific Incident Population of AKI in Hospitalized Patients in Japan, in Thousands (2019-2032)
Figure 15: Age-specific Incident Population of AKI in Japan, in Thousands (2019-2032)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security